Biomarker Consortium

GI Cancer

Pancreatic Cancer

Expert Sound Bites

KRAS Dr Balmaceda, a gastrointestinal medical oncologist at MD Anderson Cancer Center, frames the recent US Food and Drug Administration approval of daraxonrasib, a multi-selective inhibitor of the active form of RAS and the first pan-RAS targeted therapy cleared for metastatic pancreatic cancer, against the narrower allele-selective approach represented by sotorasib and adagrasib. Dr Lee, a gastrointestinal medical oncologist at Stanford University, says he cannot overstate the impact of the approval, calling it a paradigm shift that opens new treatment strategies and revives previously ineffective ones. He describes the registrational trial, which randomized patients with previously treated metastatic pancreatic cancer to daraxonrasib or investigator's choice chemotherapy and did not require a RAS mutation for entry, and reports that it met both its overall survival and progression-free survival endpoints while delivering more durable pain control and better quality of life. Dr Balmaceda previews first-line and adjuvant trials, KRAS vaccines, and known resistance mechanisms.

FDA Approval of Daraxonrasib in Pancreatic Cancer

Dr Lee, a gastrointestinal medical oncologist at Stanford University, gives a primer on reading KRAS results on a next-generation sequencing report, explaining that the letter, number, letter format identifies the codon and the amino acid change. Most pancreatic ductal adenocarcinoma mutations involve the same glycine residue, with G12D the most common, followed by G12V and G12R, while G12C, familiar from lung cancer, is uncommon here. He notes retrospective evidence that alleles differ prognostically, differing sensitivity to KRAS inhibitors, and active trial development around specific alleles. Dr Balmaceda, a gastrointestinal medical oncologist at MD Anderson Cancer Center, adds that co-mutations in TP53, CDKN2A, and SMAD4 affect genomic stability, cell cycle regulation, and the tumor microenvironment, but are not yet used to select standard therapy. Dr Lee closes by urging comprehensive sequencing at diagnosis, noting platinum sensitivity conferred by DNA repair gene mutations, and cautioning that a negative liquid biopsy cannot rule out mutations because pancreatic tumors shed little circulating tumor DNA.

KRAS Alleles and Genomic Testing in Pancreatic Cancer

Dr Balmaceda, a gastrointestinal medical oncologist at MD Anderson Cancer Center, opens with a patient who presented with abdominal pain, fatigue, and weight loss, and was found to have a pancreatic head mass with liver metastases and biopsy-confirmed pancreatic ductal adenocarcinoma. The patient responded to first-line combination chemotherapy before progressing, and comprehensive genomic profiling returned a KRAS mutation with a co-occurring TP53 alteration, microsatellite stable disease, and low tumor mutational burden. Dr Lee, a gastrointestinal medical oncologist at Stanford University, calls that a standard profile for the disease and notes that TP53 has no drug targeting it directly, while the microsatellite stable, low tumor mutational burden findings make immunotherapy unlikely to help. Dr Balmaceda then describes KRAS as an on and off switch that cycles between guanosine triphosphate and guanosine diphosphate bound states and stays locked on when mutated, and explains that molecular imaging revealed the pocket that finally made a long-standing undruggable target reachable.

KRAS Biology and Molecular Profiling in Pancreatic Cancer

Breaking New Ground in Pancreatic Cancer

ATM in PDAC

KRAS in Pancreatic Cancer

CLDN18.2 in PDAC

RAD50-RAD51 in Pancreatic Cancers

PALB2 in Pancreatic Cancers

FGFR in Pancreatic Cancers

Canonical  and Non-Canonical Homologous Recombination Gene Mutations in Pancreatic Cancer

Rare Gene Fusions in Pancreatic Cancer: Recent Updates in Biomarker and Drug Development

BRAF V600E in Pancreatic Cancer: Recent Updates in Biomarker and Drug Development

KRAS in Pancreatic Cancer: Recent Updates in Biomarker and Drug Development

BRCA Positive Pancreatic Cancer: Navigating Treatment Options

Testing for BRCA Mutations in Pancreatic Cancer

The Evolving Role of Liquid biopsy in Pancreatic Cancer

Additional Resources

EGFR-Mutated Non-Small Cell Lung Cancer: A Guide for Patients & Caregivers

Adopting Consensus Terms for Testing in Precision Medicine

Fostering a High-Functioning Team in Cancer Care Using the 4R Oncology Model

Molecular in My Pocket Reference Card Series

No One Missed Provider Campaign

Recent Updates in Molecular Targets and Pathways in Lung Cancer

Uncommon Mutations in NSCLC

Biomarkers in NSCLC

Stomach Cancer Biomarkers

Test your Biomarkers

Molecular in My Pocket Referenced Card Series – Colorectal Cancer

Biomarkers in Gastrointestinal Cancers

The Clinical Impact of Testing for Biomarkers in Gastric Cancer Patients: A Real-World Cohort

Best Practices Along the Tissue Journey in NSCLC

Improving Time to Molecular Testing Results in Patients With Newly Diagnosed, Metastatic Non–Small Cell Lung Cancer

Improving Biomarker Testing and Applying Testing Results in Clinical Practice

Tips for Assisting Uninsured Patients With Treatment Costs

Health Equity

Ferrying Oncologists Across the Chasm of Interpreting Biomarker Testing Reports: Systematic Support Needed to Improve Care and Decrease Disparities

Additional Resources

Biomarkers in NSCLC

Biomarkers in Gastrointestinal Cancers

Improving Biomarker Testing and Applying Testing Results in Clinical Practice

Addressing Barriers to Access and Improving Equity in Biomarker Testing

Websites